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As the COVID-19 pandemic developed and neurological manifestations were reported, 
concern grew that SARS-CoV-2 might directly invade neuronal cells. However, research 
throughout the year to address this concern has revealed a different story with 
inflammatory processes at its centre. 
 
Historically, the great epidemic causes of neurological disease, such as Japanese 
encephalitis and polio viruses, have directly infected the brain and spinal cord, causing 
widespread inflammation and destruction. As the pandemic of COVID-19 developed and 
increasing numbers of patients with neurological disease were reported, the question was, 
would SARS-CoV-2 behave in a similar way? 
 
Initial reports of patients with COVID-19 who exhibited clinical evidence of brain 
inflammation (from imaging or lumbar puncture) suggested that SARS-CoV-2 encephalitis 
can occur(1), though the rarity with which the virus was found in the cerebrospinal fluid 
(CSF), implied that immune-mediated damage is more important than viral replication in 
neurons. As the numbers of case reports and small series grew, it became clear that 
anosmia, encephalopathy and stroke were the predominant neurological syndromes 
associated with COVID-19(1). 
 
Anosmia and associated dysgeusia are common among people infected with SARS-CoV-2, 
and often occur in the absence of other symptoms. Herpes simplex virus type-1 infects the 
olfactory bulb and subsequently the brain, leading to encephalitis; animal models have 
shown that the same is true for some coronaviruses, including SARS-CoV-1, the cause of 
severe acute respiratory syndrome (SARS). Consequently, concerns were raised initially that 
olfactory infection with SARS-CoV-2 might lead to CNS disease. However, an elegant study 
published in July 2020 indicated that SARS-CoV-2 infects the supporting cells in the olfactory 
epithelium rather than the sensory neurons(2). 
 
In this study, single-cell RNA sequencing gene expression analysis of human nasal biopsy 
samples showed that the supporting cells, particularly sustentacular and horizontal basal 
cells, express angiotensin converting enzyme 2 (ACE2) receptors and cell surface 
transmembrane serine protease 2 (TMPRSS2), both of which are critical for viral entry, 
whereas olfactory sensory neurons do not. Immunohistochemical staining confirmed ACE2 
protein expression in these same cells. Equivalent observations were made in the mouse, 
where the deeper olfactory bulb tissue could also be examined. Here, ACE2 receptors were 
found in vascular cells, predominantly pericytes, and immune cells of the 
macrophage/monocyte lineage, but not in neurons(2). 
 
SARS-CoV-2 infection of these supporting cells could lead to anosmia via several 
mechanisms. First, the supporting cells in the olfactory epithelium are responsible for local 
water and ion balance, and damage to them can influence neuronal signalling from the 
olfactory sensory neurons to the brain. Second, infection of these cells and pericytes in the 
olfactory bulb could perturb neuronal signalling through local inflammation with cytokine 
release. Third, vascular damage and hypoperfusion in the olfactory bulb could contribute to 
impaired function. Finally, any of these changes could indirectly trigger death of the 
olfactory sensory neurons. Imaging studies in patients with COVID-19 and anosmia have 
revealed hyperintensity and swelling of the olfactory bulb, consistent with inflammation, 
which subsequently resolved, just as the symptoms do in most patients. 
 
Though anosmia is the most common neurological symptom in people with mild disease, 
alterations in higher mental function are more important among patients who are 
hospitalized with COVID-19. Terms such as encephalopathy and delirium have been used to 
describe these changes; different specialities have preferred different terms, which makes it 
challenging to compare data. 
 
In one study conducted in France, 118 (84%) of 140 consecutive patients admitted to 
intensive care units (ICUs) with COVID-19 developed delirium with a combination of acute 
disturbances in attention, awareness and cognition; 88 (69%) had corticospinal tract 
signs(3). Delirium can occur in any patient in ICU, especially if staff are wearing personal 
protective equipment and loved ones are excluded. However, accumulating data suggest we 
are seeing more than expected on this basis and that these symptoms could be 
characteristic of SARS-CoV-2 infection, especially given that delirium, encephalopathy and 
other neuropsychiatric manifestations are also seen in patients with milder respiratory and 
systemic COVID-19, who are not in ICU. 
 
Data from analysis of CSF, autopsy samples and imaging data are beginning to elucidate 
disease mechanisms that could underlie these cognitive disturbances. Typically, pleocytosis 
is not seen in CSF of individuals with encephalopathic COVID-19, but protein levels can be 
elevated with matched oligoclonal bands. Elevated plasma and CSF levels of cytokines, glial 
fibrillary acidic protein and neurofilament light chain in COVID-19 are thought to reflect a 
proinflammatory systemic and brain response that involves microglial activation and 
subsequent neuronal damage(4,5). Further evidence for inflammatory mechanisms comes 
from imaging findings in the French ICU study, which showed meningeal enhancement and 
diffuse white matter abnormalities as well as microhaemorrhages(3).  
 
In addition to inflammatory changes, coagulopathy and vascular endothelial dysfunction, 
which cause large vessel strokes in patients with COVID-19, can also lead to small vessel 
occlusions and microhaemorrhages, which could contribute to more subtle neurological and 
neuropsychiatric presentations, as suggested by clinical and imaging studies(6). However, 
the most definitive data on the underlying mechanisms come from autopsy series. One such 
study conducted in Germany included 43 individuals, most of whom died in ICUs, general 
wards or nursing homes from pneumonia or sepsis associated with COVID-19(7). Six of these 
individuals had acute ischaemic brain lesions. Activation of astrocytes was widespread 
across many brain areas, whereas activation of microglia was confined to the brainstem and 
cerebellum. Cytotoxic T cells were also seen in the brainstem and in the meninges of many 
patients. RNA detection and immunohistochemistry showed that SARS-CoV-2 was widely 
distributed throughout the brain, especially the brainstem. However, no correlation was 
seen between the location of the virus and inflammation, or indeed between PCR detection 
and immunohistochemical staining of the virus. Without double immunostaining, it is hard 
to be certain which cell types were infected in the brain, but results from an electron 
microscopy study indicates that infection of vascular endothelial cells is more likely than 
infection of neurons(8). However in an autopsy study of 33 patients, there was PCR and 
immunohistochemical evidence of SARS-CoV-2 in cells thought to be olfactory sensory 
neurons, and in anatomically connected regions of the brain(9). 
The observation that some patients with encephalopathic changes respond to 
corticosteroids, appears to underscore the importance of immune-mediated mechanisms 
rather than direct viral effects(10). 
 
In summary, if the retina is said to be the window on the brain, then for understanding 
SARS-CoV-2, the nose has perhaps been the front door. For just as SARS-CoV-2 causes 
disturbance of smell without infecting olfactory sensory neurons, the evidence to date 
suggests that the disturbance of higher mental function occurs predominantly without 
infection of CNS neurons. Although the virus can get into the brain, it seems to 
predominantly infect vascular and immune cells rather than neurons. Local inflammation 
upregulates astrocytes and microglia, which perhaps compound the effects of pro-
inflammatory cytokines in the circulation caused by severe systemic disease. Microvascular 
infarcts and haemorrhages, which are part of the systemic coagulopathy and vasculopathy 
of COVID-19, are probably also critical elements in the development of encephalopathy, 
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• Anosmia, encephalopathy and stroke are the most common neurological syndromes 
associated with SARS-CoV-2 infection1, though many others have been reported. 
 
• Analysis of human biopsy samples suggests that anosmia results predominantly  
from SARS-CoV-2 infection of non-neuronal cells in the olfactory epithelium and 
olfactory bulb2, leading to local inflammation and neuronal malfunction.  
 
• A high proportion of patients admitted to intensive care units with COVID-19 
develop delirium, and evidence suggests that this is caused by microvascular [this 
word is essential here] and inflammatory mechanisms3. 
 
• Autopsy data show activation of astrocytes and microglia in COVID-19, particularly in 
the brainstem, where there is also infiltration of cytotoxic T cells7,9. 
 
• SARS-CoV-2 can be detected in the brain with PCR and immunohistochemistry, but 
the evidence to date suggests it is mostly in vascular and immune cells rather than 







Current understanding of the predominant disease mechanism causing CNS Covid-19 
disease 
1- A systemic inflammatory disease causes activation of the vascular endothelium, a 
proinflammatory cytokine response with vascular leakage, and inflammatory cells crossing 
into the brain 
2- A prothrombotic state with activated platelets and microthrombi leads to thrombus 
formation, ischaemia and associated microhaemorrhage 
3. Virus enters the vascular endothelium and associated cells such as pericytes leading to 
activation of microglia and astrocytes, with virus occasionally entering neurons. 
 
Or shortened figure legend: 
 
Current understanding of the predominant disease mechanism causing CNS Covid-19 
disease, showing the importance of a systemic inflammatory response, prothrombotic 
state and direct viral invasion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1 
 
